Table 1.

Dosing of NOAC for stroke prevention in AF⁴³

NOAC agent	Standard dose	Reduced dose	Dose reduction criteria
Apixaban	5 mg twice daily	2.5 mg twice daily	If two of three fulfilled: body weight ≤ 60 kg, age ≥ 80 years, serum creatinine > 133 mmol/L (1.5 mg/dL). A single criterion: CrCl 15–29 mL/min
Dabigatran	150 mg twice daily, 110 mg twice daily	Not applicable	No pre-specified dose reduction criteria in the RE-LY trial. Per SmPC: 110 mg twice daily if age > 80 years, concomitant verapamil, increased risk of GI bleeding
Edoxaban	60 mg once daily	30 mg once daily	If one of three fulfilled: body weight ≤ 60 kg or CrCl 15–49 mL/min or concomitant therapy with a strong P-Gp inhibitor
Rivaroxaban	20 mg once daily	15 mg once daily	A CrCl of 15–49 mL/min

NOAC, non-vitamin K antagonist oral anticoagulant; GI, gastrointestinal; CrCl, creatinine clearance; P-Gp, P-Glycoprotein; SmPC, Summary of Product Characteristic; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy.